Globus Medical reported a robust Q3 2025, with sales increasing 22.9% to $769 million and non-GAAP EPS jumping 42.6% to $1.18, driven by strong growth in both the U.S. and international spine markets.

• Base business revenue rose to $669.8 million, with an adjusted EBITDA margin improvement of 435 basis points to 35.3%.
• Free cash flow reached a record $213.9 million, underlining operational efficiency and strong cash generation.
• The U.S. Spine segment grew by 9.6%, maintaining positive momentum with 32 consecutive weeks of growth.
• The recently acquired Nevro business contributed $99.3 million in revenue, enhancing overall business expansion.
• Strategic share repurchases totaled $40 million during the quarter, reflecting confidence in long-term growth and shareholder value.